| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
25,750,000 |
| Market
Cap: |
812.41(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.85 - $57.48 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 232 |
| Guru Rank Value : 6.7 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Harrow Health engages in the development, production and sale of medications. Co. owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical businesses. Through its subsidiaries, Visionology, Inc., which provides an online eye health platform; Surface Ophthalmics, Inc., which is focused on development and commercialization of therapeutics for ocular surface diseases; and Melt Pharmaceuticals, Inc., which is focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
257,300 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,938,957 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
13 |
| Total Shares Sold |
50,000 |
85,000 |
85,000 |
85,000 |
| Total Sell Value |
$1,459,754 |
$2,610,073 |
$2,610,073 |
$2,610,073 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
6 |
10 |
10 |
10 |
| End Date |
2025-03-27 |
2024-12-24 |
2024-06-25 |
2023-06-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Opaleye Management Inc. |
10% Owner |
– – • |
2025-06-10 |
4 |
S |
$30.80 |
$462,033 |
I/I |
(15,000) |
90,000 |
|
-2% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-06-09 |
4 |
S |
$30.37 |
$461,794 |
I/I |
(15,204) |
105,000 |
|
-5% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-06-04 |
4 |
S |
$30.02 |
$53,907 |
I/I |
(1,796) |
120,204 |
|
-7% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-06-03 |
4 |
S |
$30.04 |
$90,116 |
I/I |
(3,000) |
122,000 |
|
-8% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-05-13 |
4 |
S |
$26.59 |
$132,945 |
I/I |
(5,000) |
125,000 |
|
-21% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-05-12 |
4 |
S |
$25.90 |
$258,959 |
I/I |
(10,000) |
130,000 |
|
-19% |
|
| Boll Andrew |
Chief Financial Officer |
• – – |
2025-04-07 |
4 |
D |
$23.09 |
$3,157,442 |
D/D |
(136,745) |
777,844 |
|
- |
|
| Saharek John P. |
CEO & President, ImprimisRx |
• – – |
2025-04-07 |
4 |
D |
$23.09 |
$2,527,778 |
D/D |
(109,475) |
467,388 |
|
- |
|
| Baum Mark L |
Chief Executive Officer |
• • • |
2025-04-07 |
4 |
D |
$23.09 |
$6,935,382 |
D/D |
(300,363) |
2,599,462 |
|
- |
|
| Boll Andrew |
Chief Financial Officer |
• – – |
2025-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
346,500 |
914,589 |
|
- |
|
| Saharek John P. |
CEO & President, ImprimisRx |
• – – |
2025-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
277,200 |
576,863 |
|
- |
|
| Baum Mark L |
Chief Executive Officer |
• • • |
2025-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
762,300 |
2,899,825 |
|
- |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-03-24 |
4/A |
S |
$30.01 |
$150,055 |
I/I |
(5,000) |
140,000 |
|
- |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-03-18 |
4 |
S |
$29.64 |
$148,200 |
I/I |
(5,000) |
145,000 |
|
-18% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-02-28 |
4 |
S |
$28.05 |
$140,250 |
I/I |
(5,000) |
150,000 |
|
-13% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2025-01-22 |
4 |
S |
$35.59 |
$711,814 |
I/I |
(20,000) |
155,000 |
|
13% |
|
| Saharek John P. |
CEO of ImprimisRx |
• – – |
2024-09-11 |
4 |
D |
$41.37 |
$1,867,442 |
D/D |
(45,140) |
299,663 |
|
- |
|
| Saharek John P. |
CEO of ImprimisRx |
• – – |
2024-09-11 |
4 |
OE |
$7.37 |
$663,300 |
D/D |
90,000 |
344,803 |
|
- |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2024-04-25 |
4 |
B |
$9.97 |
$199,400 |
I/I |
20,000 |
3,815,000 |
1.5 |
300% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2024-04-24 |
4 |
B |
$10.15 |
$84,093 |
I/I |
8,285 |
3,795,000 |
1.5 |
283% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2024-04-23 |
4 |
B |
$10.29 |
$120,547 |
I/I |
11,715 |
3,786,715 |
1.5 |
292% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2024-04-19 |
4 |
B |
$10.56 |
$310,391 |
I/I |
29,400 |
3,775,000 |
1.5 |
276% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2024-03-28 |
4 |
B |
$12.82 |
$641,000 |
I/I |
50,000 |
3,745,600 |
1.5 |
156% |
|
| Baum Mark L |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-03-22 |
4 |
B |
$11.59 |
$104,310 |
D/D |
9,000 |
2,137,525 |
2.81 |
105% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2024-03-20 |
4 |
B |
$9.65 |
$488,290 |
I/I |
50,600 |
3,695,600 |
1.5 |
145% |
|
135 Records found
|
|
Page 1 of 6 |
|
|
0.16 (0.5%) 
